Introduction
============

The signaling of ischemia or ischemia-reperfusion (I-R) is a major contributing condition leading to gastric mucosal injury induced by stress,^([@B1],[@B2])^ non-steroidal anti-inflammatory drugs (NSAIDs),^([@B3])^ and *Helicobacter pylori* infection.^([@B4])^ Gastric I-R causes mucosal ulcerative lesions as well as acute inflammation associated with neutrophil accumulation.^([@B5]--[@B7])^ Previous studies have demonstrated that the infiltration of neutrophils into gastric tissue via neutrophil-endothelial cell interactions plays a critical role in the pathogenesis of I-R-induced gastric injury, because neutrophils generate tissue damage factors such as reactive oxygen species and proteases.^([@B6],[@B8])^ Neutrophil accumulation is a complex phenomenon that also involves various adhesion molecules and inflammatory mediators. Using a rat model of gastric I-R, we have revealed that reactive oxygen species play a crucial role in the pathogenesis of reperfusion-induced mucosal injury.^([@B6],[@B7])^ In addition to reactive oxygen species, a variety of cytokines, including interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α), and IL-1β, are released from post-ischemic gastric tissue to modulate tissue repair and adaptation. These cytokines are elaborated soon after gastric ischemic injury and can acutely regulate gastric mucosal survival or apoptosis and trigger additional cellular inflammatory response.

The peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor supergene family that function in ligand-activated transcription.^([@B9],[@B10])^ PPARs consist of at least three isoforms, α, β, and γ, encoded by unique genes. Among them, PPAR-γ is highly expressed in adipose tissue, colon, spleen, adrenal gland, and macrophages. Previous studies have demonstrated that the naturally occurring arachidonic acid metabolite, 15-deoxy-Δ^12,14^-prostaglandin J~2~ (15d-PGJ~2~), as well as thiazolidinedione (TZD) and certain novel non-TZD insulin-sensitizing agents, are ligands and agonist of this receptor. Although PPAR-γ play a key role in adipose differentiation, lipid metabolism, and glucose homeostasis, recent studies suggest that they might be involved in the control of inflammation and especially in the modulation of the expression of various cytokines in monocytes and macrophages.^([@B11]--[@B13])^

Recently, our group and others reported that PPAR-γ plays an anti-inflammatory role in gastric inflammation induced by I-R,^([@B14]--[@B18])^ aspirin,^([@B19])^ and *Helicobacter pylori* infection^([@B20])^ in rats. In 2001, we firstly demonstrated that pioglitazone, a synthetic TZD, markedly reduced gastric erosions induced by aspirin as well as inhibited the enhanced expression of pro-inflammatory cytokine TNF-α.^([@B19])^ In addition, we have reported the gastric cytoprotection by pioglitazone and 15d-PGJ~2~ against I-R injury, associated with anti-inflammatory actions of these ligands.^([@B14],[@B18])^ This beneficial effects by PPAR-γ ligands on I-R-induced gastric injury have been also confirmed by several investigators, however, the precise mechanism of the cytoprotection *in vivo* is not elucidated thoroughly. In addition, Nakajima *et al.*^([@B21])^ showed that no expression of PPAR-γ could be detected by Western blot analysis in the rat stomach.

On the basis of these observations, we determined the gastric localization of PPAR-γ expression in the rat gastric mucosa, and examined whether GW9662, an antagonist of PPAR-γ, can attenuate the protective effects of pioglitazone and 15d-PGJ~2~ in order to elucidate whether the protective effects of these ligands are related to the activation of the PPAR-γ receptor. Finally, to clarify the mechanism of cytoprotective properties of pioglitazone, we performed a global analysis of gene expression in the gastric mucosal cells of rats treated with pioglitazone.

Materials and Methods
=====================

Reagents
--------

All chemicals were prepared immediately before use. Pioglitazone was donated from Takeda Pharmaceutical Co., Ltd. (Osaka, Japan). 15d-PGJ~2~ and GW9662 were obtained from Cayman Chemical Co. (Ann Arbor, MI) and Sigma-Aldrich Japan Inc. (Tokyo, Japan), respectively. PPAR-γ polyclonal antibody (sc-6285) was purchased from Santa Cruz Biotech. (Santa Cruz, CA). Isogen was purchased from Nippon Gene (Tokyo, Japan), and Taq DNA polymerase was from Takara Shuzo Co. (Shiga, Japan). Enzyme-linked immunosorbent assay (ELISA) kits for TNF-α and CINC-1 were obtained from BioSource Int. (Camarillo, CA) and Immuno-Biological Laboratories Co. (Gunma, Japan). All other chemicals used were of reagent grade.

Preparation of rats for acute gastric mucosal injury induced by ischemia-reperfusion
------------------------------------------------------------------------------------

Male Sprague-Dawley rats weighing 190--210 g were obtained from Keari Co. Ltd. (Osaka, Japan). They were housed in stainless steel cages with wire bottoms and maintained on a 12-h light and 12-h dark cycle with the temperature and relative humidity of the animal room controlled at 21--23°C and 55--65%, respectively. They were not fed for 18 h prior to the experiments, but were allowed free access to water. Maintenance of animals and experimental procedures were carried out in accordance with the US National Institutes of Health Guidelines for the Use of Experimental Animals. All experiments were approved by the Animal Care Committee of Kyoto Prefectural University of Medicine (Kyoto, Japan). After animals were given intraperitoneal urethane anesthesia (1000 mg/kg), gastric ischemia was induced by applying a small clamp to the celiac artery for 30 min, followed by the removal of the clamp for 60 min according to the previously reported method.^([@B6])^ Pioglitazone dissolved in 0.5% carboxymethyl cellulose (CMC) and 15d-PGJ~2~ dissolved in physiological saline were given to the rats by gastric intubation 1 h before the vascular clamping. To evaluate the effect of agents on ischemia-reperfusion injury, mice were divided into the following groups: 1) sham-operated mice receiving 0.5% CMC solution, 2) I-R-treated mice receiving 0.5% CMC solution, 3) sham-operated mice receiving pioglitazone or 15d-PGJ~2~, and 4) I-R-treated mice receiving pioglitazone or 15d-PGJ~2~. A specific PPAR-γ antagonist GW9662 dissolved in physiological saline was also given to rats intraperitoneally 2 h before the vascular clamping.

Assessment of gastric mucosal injury induced by ischemia-reperfusion
--------------------------------------------------------------------

To estimate the severity of the gastric erosions induced by I-R, the total area of the red gastric lesions that was measured using a dissecting microscope (×10 magnification) with a square grid by a person blinded to the treatment. The extent of any gastric mucosal lesions was expressed in terms of the total area (mm^2^) of hemorrhagic erosions. Removed tissues were fixed in 15% formaldehyde, embedded in paraffin, and sectioned (5-µm slices), and the sections were stained with hematoxylin eosin and viewed by an investigator blinded to the treatment.

Cell culture and preparation for anoxia-reoxygenation
-----------------------------------------------------

The rat gastric mucosal cell line RGM-1 (RCB-0876 at Riken Cell Bank, Tsukuba, Japan), established by Matsui and Ohno,^([@B22])^ was used for the present study. The RGM-1 cells were grown in Dulbecco's modified Eagle's medium (DMEM; Gibco Laboratories, Grand Island, NY) containing 10% fetal bovine serum and antibiotics (100 U/ml penicillin, 100 µg/ml streptomycin, and 0.125 µg/ml amphotericin B). Cell cultures were incubated in atmospheric air with 5% CO~2~ at 37°C. Confluent RGM-1 monolayers were exposed to hypoxia by incubation in Plexigas chamber that was continuously purged (1 l/min) with an anoxic gas mixture (95% N~2~ + 5% CO~2~), according to a method reported in a previous study.^([@B23],[@B24])^ After a 120-min period of hypoxia, reoxygenation was initiated by exposure the cells to atmospheric air with 5% CO~2~ at 37°C for 8 h. When we pretreated RGM-1 cells with pioglitazone, we applied 1 and 10 µM pioglitazone dissolved in 0.5% dimethylsulfoxide into the culture media for 60 min before anoxia treatment.

Immunohistochemistry for PPAR-γ
-------------------------------

Expression and localization of PPAR-γ in gastric tissue was detected by standard immunohistochemical techniques using anti-PPAR-γ polyclonal antibody on paraffin sections. The mAb were diluted in PBS solutions containing 1% BSA and 0.1% Triton X-100 and applied for overnight at 4°C. The sections were then incubated with biotinylated anti-mouse IgG (Vectastatin Elite ABC kit, Vector Laboratories) for 30 min. After they were washed, the specimens were incubated with a mixture of avidin and horseradish peroxide-conjugated biotin for 30 min and were reacted with 3,3\'-diaminobenzidine tetrahydrochloride at 0.2 mg/ml and 0.005% H~2~O~2~ in Tris buffer. Nonimmune mouse IgG was used as a negative control.

Reversed transcription-polymerase chain reaction (RT-PCR)
---------------------------------------------------------

For the evaluation of PPAR-γ, TNF-α and CINC-1 mRNA, the gastric wall of rats was rinsed in PBS, snap-frozen in liquid nitrogen, and then stored at −80°C until the time of RNA extraction. Total RNA was isolated from the gastric mucosal with the acid guanidinium phenol chloroform method using an Isogen kit (Nippon Gene, Tokyo, Japan). The concentration of RNA was determined by absorbance at 260 nm in relation to absorbance at 280 nm. RNA was stored at −70°C until reverse transcription was performed. The RNA was used for reverse-transcription polymerase chain reaction (RT-PCR) amplification. The amplification was carried out in a 50 µl-mixture containing 2 µl of the RT product, 0.6 µM of both the sense and antisense primers, 0.4 mM dNTP mix, and 0.5 µl Taq DNA polymerase (Takara Shuzo Co., Shiga, Japan). The reaction was performed as follows: 35 cycles of amplication (denaturation at 94°C for 30 s, annealing at 50°C for 30 s, and extension at 72°C for 60 s), followed by a final extension step of 7 min at 72°C. Sequences for primers were: PPAR-γ forward primer 5\'-ATCGTGGGCCGCCCTAGGCA-3\'; PPAR-γ reverse primer 5\'-TGGCCTTAGGGTTCAGAGGGG-3\'; TNF-α, forward primer 5\'-ATGAGCACAGAAAGCATGATC-3\'; TNF-α, reverse primer 5\'-TACAGGCTTGTCACTCGAATT-3\'; CINC-1 forward primer sense 5\'-CTGTGCTGGCCACCAGCCGC-3\'; CINC-1 reverse primer 5\'-ACAGTCCTTGGAACTTCTCTG-3\'; and β-actin forward primer; 5\'-ATCGTGGGCCGCCCTAGGCA-3\'; β-actin reversed primer 5\'-TGGCCTTAGGGTTCAGAG GGG-3\'. The PCR reaction products were separated electrophoretically in a 2.5% agarose gel and stained by ethidium bromide.

Quantitative real-time PCR
--------------------------

After 2 h of administration with vehicle solution or pioglitazone (10 mg/kg), total RNA was isolated from the gastric mucosal with the acid guanidinium phenol chloroform method using an Isogen kit (Nippon Gene). An aliquot (1 µg) of extract RNA was reverse-transcribed into first-strand complementary DNA (cDNA) at 42°C for 40 min, using 100 U/ml reverse-transcriptase (Takara Biochemicals, Shiga, Japan) and 0.1 µM of oligo (dT)-adapter primer (Takara) in a 50 µL reaction mixture. Real-time polymerase chain reaction (PCR) was carried out with a 7300 Real Time PCR system (Applied Biosystems, Foster City, CA) using the DNA-binding dye SYBER Green I for the detection of PCR products according to the manufacturer's instructions. The reaction mixture (RT-PCR kit, Code RRO43A, Takara) contained 12.5 µl Premix Ex Taq, 2.5 µl SYBER Green I, custom-synthesized primers, ROX reference dye, cDNA (equivalent to 20 ng total RNA) to give a final reaction volume of 25 µl. Sequences for primers were:calnexin (CANX) forward primer 5\'-TGCCATCTCTGCTAAACTGAACA-3\';CANX reverse primer 5\'-CACCACCGCATT CTATTCCA-3\'; endoplasmic reticulum stress protein 72 (ERP70) forward primer 5\'-ATGCTCTCCGAG AATTTGTCATG-3\';ERP70 reverse primer 5\'-CACCCTGACTG GTCCCTTGT-3\'; heat-shock 70 kD protein 5 (HSPA5) forward primer 5\'-CCATCACCAATGACCAAAACC-3\';HSPA5 reverse primer 5\'-GCGCTCTTTGAGCTTTTTGTC-3\';heat-shock protein 86 (HSPCA) forward primer 5\'-CAGGCAGAAATTGCCCAGTT-3\';HSPCA reverse primer 5\'-AGAGCGTCTGAGGAGTTGG AAA-3\'; proteasome subunit beta type4 (PSMB4) forward primer 5\'-GAAGCAAGTTCTCGGCCAGAT-3\';PSMB4 reverse primer 5\'-ACATGGCCCTTGTCAACCA-3\';and β-actin forward primer 5\'-GAGCAAACATCCCCCAAAGTT-3\';β-actin reverse primer 5\'-GCCGTGGATACTTGGAGTGACT-3\'. The PCR settings were as follows: initial denaturation of 10 s at 95°C was followed by 40 cycle of amplification for 5 s at 95°C and 31 s at 60°C. Real-time PCR was performed with universal cycling conditions (2 min at 50°C, 10 min at 95°C, 40 cycles of 15 s at 95°C, and 1 min at 60°C). Data were analyzed using ABI Prism 7300 SDS Software (Applied Biosystems). Standard curves relating initial template copy number to fluorescence and amplification cycle were generated using the amplified PCR product as a template, and were used to calculate mRNA copy number in each sample. Ratios of the intensities of the β-actin signals were used as a relative measure of the expression level of each specimen.

Western blotting
----------------

The frozen tissue from rat stomach was thawed on ice and homogenized at 4°C in a solution of 50 mmol/l Tris-HCl, pH 7.6, 300 mmol/l NaCl, 0.5% Triton X-100, 10 mg/ml aprotinin, 10 mg/ml leuptin, 1 mmol/l PMSF, 1.8 mg/ml iodoacetamide, 50 mmol/l NaF, and 1 mM DTT for extracting total cell protein. Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose (Bio-Rad Laboratories, Hercules, CA). Membranes were probed with polyclonal antibody against PPAR-γ (Santa Cruz Biotechnology Inc. Santa Cruz, CA). The immune complexes were visualized by Western blotting with a commercial kit (ECL by Amersham, BuckinghamshI-Re, England) according to the manufacturer's recommendations.

Measurements of TNF-α and CINC-1
--------------------------------

The concentrations of inflammatory cytokines (TNF-α and CINC-1) in the supernatant of mucosal homogenates and cell culture medium were determined by rat TNF-α and CINC-1 specific enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions.

Laser capture microdissection, isolation of RNA, cDNA synthesis, cRNA amplification, and GeneChip hybridization
---------------------------------------------------------------------------------------------------------------

We used laser-assisted microdissection to obtain cell-specific RNA. Gastric epithelial cells were identified on cryostat sections (8 µm) of the specimens obtained from the stomach of the rat, and the cells were isolated by laser-assisted microdissection using an LM200 system (Olympus, Tokyo, Japan). A sample containing several hundred cells was collected from each stomach. According to the Affymetrix GeneChip Eukaryotic Small Sample Target Labeling Assay protocol (Version II). Using this protocol, we succeeded in obtaining a sufficient amount of biotinylated cRNA to perform the GeneChip analysis from the small amount of gastric epithelial cells obtained by laser captured microdissection.^([@B25])^ Labeled cRNA target was cleaned up using RNeasy columns. The fragmentation, hybridization, washing, and staining were carried out according to the instructions described in the GeneChip Expression Analysis Technical Manual. Affymetrix GeneChip arrays (Affymetrix, Santa Clara, CA) were hybridized with the biotinylated products (5 µg/chip) for 16 h at 45°C using the manufacturer's hybridization buffer. After washing the arrays, hybridized RNA was detected by staining with streptavidin-phycoery-thrin. The DNA chips were scanned using a specially designed confocal scanner (GeneChip Scanenr 3000, Affymetrix).

Statistics
----------

Data of total area of erosions, contents of cytokines, and real-time PCR analysis are expressed as mean (SEM). One-way analysis of variance (ANOVA) with Scheffe's multiple comparison test was performed when more than two groups were compared. Differences in mRNA expression determined by real-time PCR between vehicle and pioglitazone treatments were determined by Student's *t* test. A *p* value of \<0.05 was considered statistically significant. All analyses were performed using Stat View 5.0-J program (Abacus Concepts Inc. Berkeley, CA) on a Macintosh computer.

Array data analysis was carried out using Affymetrix GeneChip Operating Software (GCOS) version 1.0. GCOS analyzes image data and computes an intensity value for each probe cell. Briefly, mismatch probes act as specificity controls that allow the direct subtraction of both background and cross-hybridization signals. To determine the quantitative RNA abundance, the average difference values (i.e., gene expression levels) representing the perfect match-mismatch for each gene-specific probe family is calculated, and the fold changes in average difference values were determined according to Affymetrix algorithms and procedures. For the pathway analysis, gene probe set ID numbers were imported into the Ingenuity Pathway Analysis software (Ingenuity Systems, Mountain View, CA). The identified genes were mapped to genetic networks available in the Ingenuity database and were then ranked by a score. The score is the probability that a collection of genes is equal to or greater than the number in a network that could be achieved by chance alone. A score of 3 indicates that there is a 1/1000 chance (significance = 0.001) that the focus genes are in a network randomly. Therefore, gene sets with scores of 3 or higher have a 99.9% confidence of not being randomly generated. This score was used as the cut-off for identifying gene networks significantly affected by indomethacin.

Results
=======

Expression of PPAR-γ in rat gastric mucosa
------------------------------------------

To identify the localization of PPAR-γ within stomach, we performed immunohistochemical analysis of PPAR-γ protein. As shown inFig. 1a, the expression of PPAR-γ was observed in mucosal epithelial cells and parietal cells. Using cultured rat gastric mucosal cells (RGM-1), the nuclear-dominant localization of PPAR-γ was confirmed (Fig. [1](#F1){ref-type="fig"}b and c), although the levels of PPAR-γ expression in normal gastric mucosal cells was much lower than those of gastric cancer cells. Western blotting also showed the clear expression of PPAR-γ in the rat gastric mucosa (Fig. [1](#F1){ref-type="fig"}f), and its levels were not changed by I-R but slightly increased by the treatment with pioglitazone. RT-PCR also demonstrated the PPAR-γ mRNA expression in the gastric mucosa (Fig. [1](#F1){ref-type="fig"}g). The expression levels were slightly decreased after I-R.

Effect of PPAR-γ ligands and antagonist on I-R-induced gastric mucosal injury
-----------------------------------------------------------------------------

According to our previous studies^([@B14],[@B18])^ in which pre-treatment with pioglitazone or 15d-PGJ~2~ 1 h before the ischemia inhibited I-R-induced gastric mucosal injury in a dose-dependent manner, we used pioglitazone at a dose of 10 mg/kg and 15d-PGJ~2~ at a dose of 0.3 mg/kg and examined its pharmacological action in the present study. Neither ligand alone nor GW9662, a PPAR-γ antagonist, alone produced any macroscopic lesions in the rat stomach. I-R resulted in increase in total area of erosions developed in the glandular stomach. Both pioglitazone and 15d-PGJ~2~ significantly reduced the increase in total area of erosions after I-R, and the protective effect of these ligands was almost completely reversed by the co-administration with GW9662 (Fig. [2](#F2){ref-type="fig"}). The protective effect of pioglitazone and 15d-PGJ~2~ was confirmed histologically (data not shown). I-R resulted in large areas of epithelial crypt loss, predominantly neutrophilic infiltrate throughout the mucosa and submucosa, erosion, and mucosal bleeding. In contrast, pretreatment with pioglitazone or 15d-PGJ~2~ resulted in smaller erosions with few neutrophils.

Effects of pioglitazone on mucosal contents and mRNA expression of TNF-α and CINC-1 after I-R, and on the CINC-1 production from stimulated gastric epithelial cells
--------------------------------------------------------------------------------------------------------------------------------------------------------------------

To test if pioglitazone treatment could modulate the inflammatory response through regulation of cytokine production, we analyzed gastric mucosal levels of TNF-α and CINC-1. The gastric concentrations of TNF-α and CINC-1 increased significantly in rats treated I-R, and these increases were significantly inhibited by treatment with pioglitazone at a dose of 10 mg/kg (Fig. [3](#F3){ref-type="fig"} a and b). To further confirm the inhibitory effect of pioglitazone on TNF-α and CINC-1 production, we analyzed gastric expression of TNF-α and CINC-1 using RT-PCR yielding 225 and 907 base pair products to identify TNF-α and CINC-1 gene expression, respectively. As shown in Fig. [3](#F3){ref-type="fig"}c, we found the expression of these genes in the rat treated with sham-operation to be negligible or faint. In contrast, transcription was readily shown in I-R-treated rats. Treatment with pioglitazone suppressed mRNA expression for each gene. In addition, pioglitazone markedly inhibited the CINC-1 production from RGM-1 cells stimulated by 2 h-anoxia and 6 h-reoxygenation (Fig. [3](#F3){ref-type="fig"}d).

Identification of genes differentially expressed in pioglitazone-treated gastric mucosa
---------------------------------------------------------------------------------------

We next asked what genes are modulated following treatment of gastric mucosa with pioglitazone and if there are differences between the affected gene networks in pioglitazone-treated mucosa compared to non-treated mucosa. Among the 1,032 probes (Rat Toxicology U34 array, Affymetrix), the number of genes, the expression levels of which increased or decreased more than 1.5-fold in pioglitazone-treated mucosa, was 35 including 10 ESTs. 18 probes were up-regulated and 17 were down-regulated (Table [1](#T1){ref-type="table"}). Table [2](#T2){ref-type="table"} showed a gene network affected by pioglitazone, which obtained a most highest score (score 14) as defined by the Pathway Analysis, and Fig. [4](#F4){ref-type="fig"} demonstrated the associated network that was significantly affected by pioglitazone. The shown network was significantly associated with cell cycle, cell-to-cell signaling and interaction, and cancer. This network included CANX, ERP70, heat-shock protein 60 (HSP60), HSPA5, HSPCA, and PSMB4 genes.

Real time PCR for CANX, ERP70, HSP60, HSPA5, and HSPCA genes
------------------------------------------------------------

To confirm the data derived from GeneChip analysis, we further validated the expression of some genes by real-time quantitative PCR. As shown in Fig. [5](#F5){ref-type="fig"}, real time PCR study showed that the expression of CANX, ERP70, HSPCA, and PSMB4, but not HSPA5, was significantly increased by the treatment with pioglitazone.

Discussion
==========

In the present, we demonstrated the gastric expression of PPAR-γ in rats by the immunohistochemistry and Western blotting using a monoclonal antibody for PPAR-γ, and by mRNA expression for PPAR-γ, and showed that GW9662, a PPAR-γ antagonist, reversed the gastro-protective effects of pioglitazone and 15d-PGJ~2~ against I-R injury. In addition, enhanced expression of proinflammatory cytokines in the stomach after I-R was markedly inhibited by pioglitazone. Finally, the global analysis of mRNA expression of gastric mucosal cells obtained by the microdissection showed that up- and down-regulated genes after the pioglitazone treatment, and that anti-inflammatory effects of pioglitazone may be associated with the up-regulation of HSPs and endoplasmic reticulum-related proteins.

The most striking findings of the present study are that expression of PPAR-γ is observed in mainly gastric epithelial cells *in vivo* and in cultured normal gastric epithelial cell line, which was confirmed by immunohistochemistry, Western blot, and RT-PCR. This is the first report in which the gastric PPAR-γ expression in rats is confirmed. More interestingly, the expression of PPAR-γ protein in the stomach was enhanced after the treatment of pioglitazone without increased mRNA transcription, indicating that pioglitazone may stabilize the protein of PPAR-γ. In contrast to a previous report uisng renal cells by Matsuyama *et al.*,^([@B26])^ PPAR-γ expression was not enhanced after ischemia-reperfusion in rats. Although the mechanism in regulating gastric mucosal PPAR-γ expression is still unknown, the present data using DNA microarray may give possible information about it.

In order to confirm whether the protective effect of PPAR-γ ligands is due to activation of PPAR-γ, we have investigated whether the PPAR-γ antagonist GW9662 attenuates the observed protective effects of these ligands. We demonstrate here that GW966 completely reversed the gastro-protective effects of pioglitazone and 15d-PGJ~2~ against I-R injury. Recently, Wada *et al.*^([@B17])^ further defined the protective effects of endogenous PPAR-γ activity in gastric injury induced by I-R through an examination of PPAR-γ-deficient mice. They provided strong evidence in support of an important role for endogenous PPAR-γ activity in protecting from I-R injury in the stomach. Taken together, these findings support the view that the activation of PPAR-γ contributes to the protective and anti-inflammatory effects of PPAR-γ ligands in rats subjected to gastric I-R.

The next meaningful finding of the present study is that treatment with pioglitazone significantly inhibited I-R-driven activation of proinflammatory cytokines (CINC-1 and TNF-α) both *in vivo* (gastric mucosa) and *in vitro* (cultured gastric epithelial cells). We demonstrated that, in I-R-induced gastric inflammation, the expression of pro-inflammatory cytokines (CINC-1 and TNF-α) was enhanced in association with neutrophil accumulation, as determined by myeloperoxidase activity in the homogenate of the stomach.^([@B27])^ These results suggest a transcriptional mechanism by which PPAR-γ agonists may protect against gastric mucosal injury via an inhibition of cytokine production.

Finally, to investigate cytoprotective action by pioglitazone further, we compared the gene expression profiles between vehicle- and pioglitazone-treated gastric mucosal cells. By the pathway analysis, we demonstrated the associated network that was significantly affected by pioglitazone. The shown network was associated with cell cycle, cell-to-cell signaling and interaction, and cancer. This network includes CANX, ERP70, HSP60, HSPA5, HSPCA, and PSMB4 genes, and the mRNA expression of these genes were also confirmed by real-time PCR. In eukaryotic cells, the endoplasmic reticulum (ER) plays an essential role in the synthesis and maturation of a variety of important secretary and membrane proteins. For glycoprotein, the ER possesses a dedicated maturation system, which assists folding and ensures the quality of final products before ER release. Essential components of this system include the lectin chaperones CANX and calreticulin (CRT) and their associated co-chaperone ERP, a glycoprotein specific thiol-disulfide oxidoreductase.^([@B28])^ These data suggest that ER stress response induced by pioglitazone may be associated with its anti-inflammatory or cytoprotective actions on gastric mucosa. This hypothesis is supported by a recent report, in which 15d-PGJ~2~ a PPAR-γ ligand, induced ER stress, and that ER stress activation was associated with an attenuation of cytokine signaling in pancreatic β-cells.^([@B29])^

In summary, we confirmed the expression of PPAR-γ in the rat gastric mucosa, and determined that the gastroprotective action of PPAR-γ ligand was dependent on the activation of the PPAR-γ receptor. Finally, we demonstrated that DNA microarray was a highly effective way to generate a novel hypothesis on mechanism of action of PPAR-γ ligand. In conclusion, activation of PPAR-γ may represent a novel therapeutic approach for the therapy of gastric inflammation.
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![(a) Immunohistochemical staining for PPAR-γ in stomach tissue of rats. (b--e) Nuclear localization of PPAR-γ in RGM-1 cells (b, ×50, c, ×200, e, negative control) and MKN45 cells (d, ×200). (f) Western blot detection of PPAR-γ protein in homogenates of gastric mucosal tissues before and after ischemia-reperfusion (I-R). (g) Expression of *PPAR-*γ mRNA in the gastric mucosa determined by RT-PCR. 1, sham-operation, 2, ischemia-reperfusion, 3, ischemia-reperfusion + pioglitazone (10 mg/kg), 4, sham + pioglitazone.](jcbn10-81f01){#F1}

![Effect of pioglitazone and 15-deoxy-Δ^12,14^-prostaglandin J~2~ (15d-PGJ~2~) on acute gastric mucosal injury induced by ischemia-reperfusion (I-R) in rats. Multiple hemorrhagic erosions with acute edema developed in the glandular stomach of rats after 30-min ischemia and 60-min reperfusion, and pioglitazone (10 mg/kg) and 15d-PGJ~2~ (0.3 mg/kg) significantly inhibited the total area of gastric erosions induced by I-R. GW9662 significantly reversed the inhibition by these ligands against I-R-induced gastric injury. Data are expressed as mean (SEM) of 7 rats. ^\#^*p*\<0.05 when compared to control rats treated with I-R, and ^+^*p*\<0.05 when compared to rats treated with I-R plus pioglitazone or dimethyl PGJ~2~.](jcbn10-81f02){#F2}

![Effect of pioglitazone on CINC-1 contents (A), TNF-α contents (B), the gastric expression of CINC-1/TNF-α mRNA determined RT-PCR (C), and CINC-1 production from RGM-1 cells stimulated by anoxia-reoxygenation (D). The concentration of CINC-1/TNF-α in the supernatant of mucosal homogenates was determined by ELISA kit specific for rat CINC-1 and rat TNF-α. (A, B); Value reported as the mean ± SE of 6 to 8 rats. ^†^*p*\<0.01 when compared to sham-operated rats receiving 0.5% CMC solution (vehicle) alone, and ^\#^*p*\<0.05 when compared to rats receiving vehicle plus ischemia-reperfusion (I-R). (C); A representative 2% agarose gel of RT-PCR products for CINC-1 and TNF-α mRNA is shown, also including β-actin mRNA. (D); ^†^*p*\<0.01 when compared to normoxia (N), and ^\#^*p*\<0.05 when compared to anoxia-reoxygenation (A/R).](jcbn10-81f03){#F3}

![A network of genes commonly regulated after pioglitazone treatment. Seven genes that were up-regulated in pioglitazone-treated stomach were analyzed by the Ingenuity Pathway Analysis tool. The shown major network that was found to be significantly up-regulated by pioglitazone was associated with cell cycle, cell-to-cell signaling and interaction, and cancer. Shaded genes are the genes identified by microarray analysis and others are those associated with the regulated genes based on the pathway analysis. The meaning of the node shapes is also indicated. Asterisks indicate genes that were identified multiple times.](jcbn10-81f04){#F4}

![Quantitative real-time PCR for genes up-regulated by pioglitazone treatment. cDNA was prepared from gastric mucosa, and PCR was performed using an ABI 7300. The bars show levels of expression of each gene normalized to that of β-actin.](jcbn10-81f05){#F5}

###### 

Selected genes up- or down-regulated by pioglitazone treatment in rats

  Probe Set ID         Description                                                                       Pioglitazone   Normal   Log Ratio   Fold difference          
  -------------------- --------------------------------------------------------------------------------- -------------- -------- ----------- ----------------- ------ ----------
  Up-regulated                                                                                                                                                        
   rc_AI236601_at      strong similarity to mouse heat-shock protein 105 kDa,110 kDa protein             404.4          P        101.1       A                 3.1    **8.57**
   rc_AI176546_at      heat shock protein 86                                                             2691.4         P        724         P                 2      **4**
   K00996mRNA_s\_at    cytochrome P450, 2b19                                                             1098.4         P        400         A                 1.7    **3.25**
   rc_AI010725_g\_at   calnexin                                                                          614.6          P        126.2       A                 1.7    **3.25**
   J05132_s\_at        UDP glycosyltransferase 1 family, polypeptide A6                                  8504.1         P        2629.8      P                 1.4    **2.64**
   M14050_s\_at        heat shock 70kD protein 5                                                         853            P        374.2       P                 1.4    **2.64**
   rc_AI009141_at      Transcribed sequences                                                             315.8          P        141.9       A                 1.4    **2.64**
   rc_AI236795_s\_at   Rattus norvegicus heat\[-\]shock protein 90 beta mRNA, partial sequence           6173.3         P        2105.4      P                 1.4    **2.64**
   L17127_g\_at        proteasome (prosome, macropain) subunit, beta type 4                              772.1          P        286.7       P                 1.3    **2.46**
   rc_AI172452_at      weak similarity to cytochrome-c oxidase (EC 1.9.3.1) chain VIIa precursor - rat   1114.6         P        363.5       A                 1.3    **2.46**
   rc_AA859957_at      moderate similarity to NADH dehydrogenase 1 beta subcomplex, 4                    1152.9         P        706         A                 1.2    **2.3**
   rc_AI010725_at      calnexin                                                                          686.4          P        356.8       P                 1.1    **2.14**
   M86870_at           protein disulfide isomerase\[-\]related protein (calcium-binding protein)         465.7          P        239.4       P                 0.8    **1.74**
   X54793_at           heat shock protein 60 (liver)                                                     1504.5         P        816.4       P                 0.8    **1.74**
  Down-regulated                                                                                                                                                      
   rc_AA891651_g\_at   moderate similarity to NADH dehydrogenase acyl carrier chain, mitochondrial       348            A        705.1       P                 −0.8   **0.57**
   rc_AA818226_s\_at   cytochrome *c* oxidase, subunit 4a                                                2388.7         P        5302.6      P                 −0.9   **0.54**
   rc_AA900199_s\_at   Rattus norvegicus DD6C4-4 mRNA, partial sequence                                  345.5          M        695.8       P                 −0.9   **0.54**
   rc_AA892041_at      peroxiredoxin 6                                                                   411.5          A        849.8       P                 −1.2   **0.44**
   rc_AI102505_g\_at   cytochrome *c* oxidase, subunit VIIIa                                             1560           P        3382.2      P                 −1.3   **0.41**
   rc_AI177256_at      Transcribed sequences                                                             263.6          A        986.5       P                 −1.5   **0.35**
   rc_AA963674_at      eukaryotic translation elongation factor 2                                        1132.1         A        3972.2      P                 −1.6   **0.33**
   Z78279_at           collagen, type 1, alpha 1                                                         146.9          A        327.3       M                 −1.7   **0.31**
   rc_AA945054_s\_at   cytochrome b5                                                                     186.3          A        637.5       P                 −1.9   **0.27**
   J05425cds_s\_at     cytochrome *c* oxidase, subunit 4a                                                218.9          A        1097.6      P                 −2.7   **0.15**

###### 

Genetic networks up-regulated by pioglitazone treatment analyzed by Pathway Analysis

  Network ID   Genes in Network                                                                                                                                                                                                                                                        Score   Focus Genes   Top Function
  ------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------- ------------- ------------------------------------------------------------
  1            APOB, BACE, **CANX\***, CDK4, **ERP70**, GAPD, **HSP60**, HSPA4, **HSPA5**, **HSPCA**, IGK@, MYC, PPP1CC, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB1, PSMB10, PSMB2, PSMB3, **PSMB4**, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, SERPINA1, TRA@, TYR, TYRP1, VWF   14      6             Cell cycle, Cell-to-Cell Signaling and Interaction, Cancer

**Bold - Up\[-\]regulated fo\[c\]us genes.**Gene/Protein identified that made the user-defined cutoff and map to the Global Molecular Network are displayed with bold text. \*-Duplicates. Gene IDs marked with asterisks indicate that multiple identifiers from our input list mapped to a single gene in the Global Molecular Network.

CANX, calnexin; ERP70, endoplasmic reticulum stress protein 72; HSP60, heat-shock protein 60; HSPA5, heat-shock 70 kD protein 5; HSPCA, heat-shock protein 86; PSMB4, proteasome subunit beta type4.
